Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge.


Journal

PLoS biology
ISSN: 1545-7885
Titre abrégé: PLoS Biol
Pays: United States
ID NLM: 101183755

Informations de publication

Date de publication:
11 2021
Historique:
received: 12 05 2021
accepted: 17 10 2021
revised: 16 11 2021
pubmed: 5 11 2021
medline: 15 12 2021
entrez: 4 11 2021
Statut: epublish

Résumé

The emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has resulted in a pandemic causing significant damage to public health and the economy. Efforts to understand the mechanisms of Coronavirus Disease 2019 (COVID-19) have been hampered by the lack of robust mouse models. To overcome this barrier, we used a reverse genetic system to generate a mouse-adapted strain of SARS-CoV-2. Incorporating key mutations found in SARS-CoV-2 variants, this model recapitulates critical elements of human infection including viral replication in the lung, immune cell infiltration, and significant in vivo disease. Importantly, mouse adaptation of SARS-CoV-2 does not impair replication in human airway cells and maintains antigenicity similar to human SARS-CoV-2 strains. Coupled with the incorporation of mutations found in variants of concern, CMA3p20 offers several advantages over other mouse-adapted SARS-CoV-2 strains. Using this model, we demonstrate that SARS-CoV-2-infected mice are protected from lethal challenge with the original Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), suggesting immunity from heterologous Coronavirus (CoV) strains. Together, the results highlight the use of this mouse model for further study of SARS-CoV-2 infection and disease.

Identifiants

pubmed: 34735434
doi: 10.1371/journal.pbio.3001284
pii: PBIOLOGY-D-21-01241
pmc: PMC8594810
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e3001284

Subventions

Organisme : NIAID NIH HHS
ID : R21 AI145400
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI090023
Pays : United States
Organisme : NIH HHS
ID : P51 OD011132
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI153602
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR001440
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007526
Pays : United States
Organisme : NIAID NIH HHS
ID : R24 AI120942
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI147623
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI060549
Pays : United States

Commentaires et corrections

Type : UpdateOf

Déclaration de conflit d'intérêts

We have read the journal’s policy and the authors of this manuscript have the following competing interests: XX, P-YS, and VDM have filed a patent on the reverse genetic system and reporter SARS-CoV-2. Other authors declare no competing interests.

Références

Nature. 2021 Mar;591(7849):293-299
pubmed: 33494095
Science. 2020 May 29;368(6494):942-943
pubmed: 32467379
J Virol. 2015 Feb;89(4):1954-64
pubmed: 25428871
J Virol. 2020 Sep 15;94(19):
pubmed: 32699094
Viruses. 2020 Jan 24;12(2):
pubmed: 31991541
mBio. 2013 Apr 30;4(3):e00165-13
pubmed: 23631916
Nat Commun. 2020 Aug 13;11(1):4059
pubmed: 32792628
J Virol. 2011 Jan;85(1):217-30
pubmed: 20980507
PLoS Pathog. 2007 Jan;3(1):e5
pubmed: 17222058
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
J Microbiol Immunol Infect. 2021 Feb;54(1):12-16
pubmed: 32425996
Virus Res. 2008 Apr;133(1):45-62
pubmed: 17416434
Lancet. 2021 Apr 17;397(10283):1421-1423
pubmed: 33844964
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Immunol Res. 2014 Aug;59(1-3):118-28
pubmed: 24845462
Cell. 2020 Nov 12;183(4):1070-1085.e12
pubmed: 33031744
Nat Protoc. 2021 Mar;16(3):1761-1784
pubmed: 33514944
bioRxiv. 2021 Mar 09;:
pubmed: 33758836
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Expert Rev Vaccines. 2009 Jul;8(7):887-98
pubmed: 19538115
Elife. 2021 Sep 28;10:
pubmed: 34581669
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Nucleic Acids Res. 2014 Jan;42(2):e11
pubmed: 24137010
Science. 2020 Sep 25;369(6511):1603-1607
pubmed: 32732280
J Virol. 2019 Oct 29;93(22):
pubmed: 31462558
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Cell Host Microbe. 2020 May 13;27(5):841-848.e3
pubmed: 32289263
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
J Mol Biol. 2015 Aug 14;427(16):2610-6
pubmed: 26116762
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3048-53
pubmed: 26976607
Emerg Infect Dis. 2020 Jun;26(6):1266-1273
pubmed: 32160149
J Virol. 2007 Jan;81(2):813-21
pubmed: 17079315
medRxiv. 2021 Jan 20;:
pubmed: 33501468
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nucleic Acids Res. 2017 Jan 4;45(D1):D313-D319
pubmed: 27899672
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303
pubmed: 29788355
J Cell Physiol. 2021 Oct;236(10):7045-7057
pubmed: 33755190
Nat Med. 2015 Dec;21(12):1508-13
pubmed: 26552008
J Virol. 2012 Jan;86(2):884-97
pubmed: 22072787
Genome Res. 2017 Mar;27(3):491-499
pubmed: 28100584
mBio. 2013 Aug 06;4(4):
pubmed: 23919993
PLoS One. 2014 Nov 19;9(11):e112963
pubmed: 25409509
J Virol. 2013 Apr;87(7):3885-902
pubmed: 23365422
JCI Insight. 2021 Aug 23;6(16):
pubmed: 34237028
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
Cell Host Microbe. 2021 Apr 14;29(4):508-515
pubmed: 33789086
Nat Immunol. 2020 Nov;21(11):1327-1335
pubmed: 32839612

Auteurs

Antonio Muruato (A)

Departments of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Michelle N Vu (MN)

Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Bryan A Johnson (BA)

Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Meredith E Davis-Gardner (ME)

Department of Pediatrics, Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, United States of America.

Abigail Vanderheiden (A)

Department of Pediatrics, Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, United States of America.

Kumari Lokugamage (K)

Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Craig Schindewolf (C)

Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Patricia A Crocquet-Valdes (PA)

Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Rose M Langsjoen (RM)

Departments of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Jessica A Plante (JA)

Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
World Reference Center of Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, Texas, United States of America.

Kenneth S Plante (KS)

Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
World Reference Center of Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, Texas, United States of America.

Scott C Weaver (SC)

Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
World Reference Center of Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, Texas, United States of America.
Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, Texas, United States of America.

Kari Debbink (K)

Department of Natural Science, Bowie State University, Bowie, Maryland, United States of America.

Andrew L Routh (AL)

Departments of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, Texas, United States of America.

David Walker (D)

Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Mehul S Suthar (MS)

Department of Pediatrics, Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Yerkes National Primate Research Center, Atlanta, Georgia, United States of America.

Pei-Yong Shi (PY)

Departments of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, Texas, United States of America.

Xuping Xie (X)

Departments of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Vineet D Menachery (VD)

Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
World Reference Center of Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, Texas, United States of America.
Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, Texas, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH